Using metoprolol (β1-AR antagonist) and candesartan concomitantly with epirubicin-based anthracycline therapy increased circulating cardiovascular biomarkers without association with a decline in ventricular function in early BC women. This evidence concerns the gene ADRB1 and breast cancer.